A humanised mouse model of cytokine release: Comparison of CD3-specific antibody fragments

Journal of Immunological Methods

Volumn 384, Issue 1-2, 2012, Pages 33-42

  Malcolm, S L ^a   Smith, E L ^a   Bourne, T ^a   Shaw, S ^a  

^a UCB Celltech   (United Kingdom)

Author keywords

Cytokine release; Human PBMC; OKT3; SCID mouse

Indexed keywords

CD3 ANTIBODY; MALEIMIDE; OKT 3;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; COMPARATIVE STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD3; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOLOGIC TECHNIQUES; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, SCID; MUROMONAB-CD3; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES;

MUS;

EID: 84865600938     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.07.001     Document Type: Article

References (56)

1. Abbs I.C., Clark M., Waldmann H., Chatenoud L., Koffman C.G., Sacks S.H. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Ther. Immunol. 1994, 1:325.
2. Adair J.R., Athwal D.S., Bodmer M.W., Bright S.M., Collins A.M., Pulito V.L., Rao P.E., Reedman R., Rothermel A.L., Xu D., Zivin R.A., Jolliffe L.K. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum. Antibodies Hybridomas 1994, 5:41.
3. Alegre M.L., Vandenabeele P., Depierreux M., Florquin S., Deschodt-Lanckman M., Flamand V., Moser M., Leo O., Urbain J., Fiers W. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J. Immunol. 1991, 146:1184.
4. Alegre M.L., Peterson L.J., Xu D., Sattar H.A., Jeyarajar D.R., Kowalkowski K., Thistlethwaite J.R. A non-activating humanized anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994, 57:1537.
5. Alegre M.L., Tso J.Y., Sattar H.A., Smith J., Desalle, Cole M., Bluestone J.A. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 1995, 155:1544.
6. Berney T., Molano R.D., Pileggi A., Cattan P., Li H., Ricordi C., Inverardi L. Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes. Transplantation 2001, 72:133.
7. Bolt S., Routledge E., Lloyd I., Chatenoud L., Pope H., Gorman S.D., Clark M., Waldmann H. The generation of a humanised, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 1993, 23:403.
8. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin. J. Oncol. Nurs. 2007, 11:37.
9. Brown W. Anti-CD3 antibody. Curr. Opin. Investig. Drugs 2006, 7:381.
10. Bugelski P.J., Achuthanandam R., Capocasale R.J., Treacy G., Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev. Clin. Immunol. 2009, 5:499.
11. Carpenter P.A., Pavlovic S., Tso J.Y., Press O.W., Gooley T., Yu X.Z., Anasetti C. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 2000, 165:6205.
12. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 2003, 3:123.
13. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found. Symp. 2003, 252:279.
14. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 2007, 7:622.
15. Chatenoud L., Baudrihaye M.F., Kreis H., Goldstein G., Schindler J., Bach J.F. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur. J. Immunol. 1982, 12:979.
16. Chatenoud L., Ferran C., Reuter A., Legendre C., Gevaert Y., Kreis H., Franchimont P., Bach J.F. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N. Engl. J. Med. 1989, 320:1420.
17. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., Gevaert Y., Kreis H., Franchimont P., Bach J.-F. In vivo cell activation following OKT3 administration. Transplantation 1990, 49:697.
18. Chatenoud L., Thevet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:123.
19. Chatenoud L., Primo J., Bach J.F. CD3 antibody-induced dominant self-tolerance in overtly diabetic NOD mice. J. Immunol. 1997, 158:2947.
20. Chavin K.D., Qin L., Lin J., Kaplan A.J., Bromberg J.S. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993, 55:901.
21. Chung C.H. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008, 13:725.
22. Cosimi A.B., Burton R.C., Colvin R.B., Goldstein G., Delmonico F.L., LaQuaglia M.P., Tolkoff-Rubin N., Rubin R.H., Herrin J.T., Russell P.S. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981, 32:535.
23. Debure A., Chkoff N., Chatenoud L., Lacombe M., Campos H., Noël L.H., Goldstein G., Bach J.F., Kreis H. One-month prophypactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 1988, 45:546.
24. Friend P.J., Hale G., Chatenoud L., Rebello P., Bradley J., Thiru S., Phillips J.M., Waldmann H. Phase I study of an engineered aglycosylated humanised CD3 antibody in renal transplant rejection. Transplantation 1999, 68:1632.
25. Henell K.R., Norman D.J. Monitoring OKT3 treatment: pharmacodynamic and pharmacokinetic measures. Transplant. Proc. 1993, 25(Suppl. 1):83.
26. Henell K.R., Bakke A., Kenny T.A., Kimball J.A., Barry J.M., Norman D.J. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies. Transplant. Proc. 1991, 23:1070.
27. Hering B.J., Kandaswamy R., Harmon J.V., Ansite J.D., Clemmings S.M., Sakai T., Paraskevas S., Eckman P.M., Sageshima J., Nakano M., Sawada T., Matsumoto I., Zhang H.J., Sutherland D.E., Bluestone J.A. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. 2004, 4:390.
28. Herold K.C., Bluestone J.A., Montag A.G., Parihar A., Wiegner A., Gress R.E., Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992, 41:385.
29. Herold K.C., Hagopian W., Auger J.A., Poumian-Riuz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type I diabetes mellitus. N. Engl. J. Med. 2002, 346:1692.
30. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J. Clin. Invest. 2003, 111:409.
31. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763.
32. Herold K.C., Gitelman S., Greenbaum C., Puck J., Hagopian W., Gottlieb P., Sayre P., Bianchine P., Wong E., Seyfert-Margolis V., Bourcier K., Bluestone J.A. Immune Tolerance Network ITN007AI Study Group, treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 2009, 132:166.
33. Hirsch R., Bluestone J.A., DeNenno L., Gress R.E. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990, 49:1117.
34. Hsu D.H., Shi J.D., Homola M., Rowell T.J., Moran J., Levitt D., Druilhet B., Chinn J., Bullock C., Klingbeil C. A humanised anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation 1999, 68:545.
35. Kang S.P., Saif M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer - identification, prevention and management. J. Support. Oncol. 2007, 5:451.
36. Keymeulen B., Vandemeulebrocke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.-M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.-F., Pipeleers D., Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598.
37. King D.J., Turner A., Farnsworth A.P., Adair J.R., Owens R.J., Pedley R.B., Baldock D., Proudfoot K.A., Lawson A.D., Beeley N.R. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 1994, 54:6176.
38. Krutmann J., Kirnbauer R., Köck A., Schwarz T., Schöpf E., May L.T., Sehgal P.B., Luger T.A. Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3 induced T cell activation. J. Immunol. 1990, 145:1337.
39. Leo O., Foo M., Sachs D.H., Samelson L.E., Bluestone J.A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:1374.
40. Lim L.C., Koh L.P., Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J. Clin. Oncol. 1999, 17:1962.
41. Norman D. Mechanisms of action and overview of OKT3. Ther. Drug Monit. 1995, 17:615.
42. Panelli M.C., White R., Foster M., Martin B., Wang E., Smith K., Marincola F.M. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2004, 2:17.
43. Popma S.H., Griswold D.E., Li L. Anti-CD3 antibodies OKT3 and hOKT3γ1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; a specific T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. Int. Immunopharmacol. 2005, 5:155.
44. Rinnooy Kan E.A., Wright S.D., Welte K., Wang C.Y. Fc receptors on monocytes cause OKT3-treated lymphocytes to internalise T3 and to secrete IL-2. Cell. Immunol. 1986, 98:181.
45. Schaumann W., Kaufmann B., Neubert P., Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur. J. Clin. Pharmacol. 1986, 30:527.
46. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., Bode B., Aronoff S., Holland C., Carlin D., King K.L., Wilder R.L., Pillemer S., Bonvini E., Johnson S., Stein K.E., Koenig S., Herold K.C., Daifotis A.G. For the Protégé trial investigators, Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results froma randomised, placebo-controlled trial. Lancet 2011, 378:487.
47. Smith J.A., Bluestone J.A. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr. Opin. Immunol. 1997, 9:648.
48. Smith J.A., Tso J.Y., Clark M.R., Cole M.S., Bluestone J.A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 1997, 185:1413.
49. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018.
50. Utset T.O., Auger J.A., Peace D., Zivin R.A., Xu D., Jolliffe L., Alegre M.L., Bluestone J.A., Clark M.R. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 2002, 29:1907.
51. Waid T.H., Lucas B.A., Thompson J.S., Wade McKeown J., Brown S., Kryscio R., Skeeters L.J. Treatment of renal allograft rejection with T10B9.IA31 or OKT3. Transplantation 1997, 64:274.
52. Wesselborg S., Janssen O., Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 1993, 150:4338.
53. Wilde M.I., Goa K.L. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996, 51:865.
54. Wing M. Monoclonal antibody first dose cytokine release syndromes - mechanisms and predictions. J. Immunotoxicol. 2008, 5:11.
55. Woodle E.S., Xu D., Zivin R.A., Auger J., Charette J., O'Laughlin R., Peace D., Jollife L.K., Haverty T., Bluestone J.A., Thistlethwaite J.R. Phase I trial of a humanised, Fc-receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999, 68:608.
56. Xu D., Alegre M.L., Varga S.S., Rothermel A.L., Collins A.M., Pulito V.L., Hanna L.S., Dolan K.P., Parren P.W., Bluestone J.A., Jolliffe L.K., Zivin R.A. In vitro characterisation of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 2000, 200:16.